These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31875303)

  • 1. Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours.
    Iacovazzo D; Chiloiro S; Carlsen E; Bianchi A; Giampietro A; Tartaglione T; Bima C; Bracaccia ME; Lugli F; Lauretti L; Anile C; Gessi M; Colosimo C; Rindi G; Pontecorvi A; Korbonits M; De Marinis L
    Endocrine; 2020 Mar; 67(3):651-658. PubMed ID: 31875303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs.
    Chiloiro S; Giampietro A; Gessi M; Lauretti L; Mattogno PP; Cerroni L; Carlino A; De Alessandris QG; Olivi A; Rindi G; Pontecorvi A; De Marinis L; Doglietto F; Bianchi A
    J Neuroendocrinol; 2023 Apr; 35(4):e13263. PubMed ID: 37078422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Acta Neuropathol Commun; 2019 Nov; 7(1):172. PubMed ID: 31703742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
    Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
    Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.
    Chinezu L; Vasiljevic A; Trouillas J; Lapoirie M; Jouanneau E; Raverot G
    Eur J Endocrinol; 2017 Feb; 176(2):195-201. PubMed ID: 27913611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Proteomic-Based Molecular Characterizations of Invasive and Noninvasive Somatotroph PitNETs.
    Chen M; Duan L; Sun W; Guo Z; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H
    Neuroendocrinology; 2023; 113(9):971-986. PubMed ID: 37253344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
    Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
    Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the tumour microenvironment in the angiogenesis of pituitary tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Dorward N; Grieve J; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    Endocrine; 2020 Dec; 70(3):593-606. PubMed ID: 32946040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s.
    Guaraldi F; Zoli M; Righi A; Gibertoni D; Marino Picciola V; Faustini-Fustini M; Morandi L; Bacci A; Pasquini E; Mazzatenta D; Asioli S
    Clin Endocrinol (Oxf); 2020 Jul; 93(1):36-43. PubMed ID: 32306401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?
    Martínez-López S; García-Martínez A; Torregrosa-Quesada ME; López-Muñoz B; Cámara R; Fajardo C; Lamas C; Picó A
    J Endocrinol Invest; 2020 Jun; 43(6):859-863. PubMed ID: 31898311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment.
    Tanno L; Naheed S; Dunbar J; Tod J; Lopez MA; Taylor J; Machado M; Green B; Ashton-Key M; Chee SJ; Wood O; Pearce NW; Thomas GJ; Friedmann PS; Cave J; Ottensmeier CH
    Neuroendocrinology; 2022; 112(4):370-383. PubMed ID: 34157710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly.
    Zawada NB; Kunert-Radek J; Pawlikowski M; Pisarek H; Radek M
    Endokrynol Pol; 2016; 67(3):292-8. PubMed ID: 27345147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem Cell Transcription Factor Sox2 Is Expressed in a Subset of Folliculo-stellate Cells of Growth Hormone-Producing Pituitary Neuroendocrine Tumours and Its Expression Shows No Association with Tumour Size or IGF1 Levels: a Clinicopathological Study of 109 Cases.
    Soukup J; Česák T; Hornychová H; Michalová K; Michnová Ľ; Netuka D; Čáp J; Gabalec F
    Endocr Pathol; 2020 Dec; 31(4):337-347. PubMed ID: 32632839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor expression and clinical outcome of multilineage pituitary tumours expressing PIT1 and SF1.
    Fookeerah P; Varikatt W; Shingde M; Dexter MAJ; McLean M
    Endocr Connect; 2023 Nov; 12(11):. PubMed ID: 37851558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Awad S; Dorward N; Grieve J; Mendoza N; Muquit S; Grossman AB; Balkwill F; Korbonits M
    Endocr Relat Cancer; 2019 Dec; 26(12):853-865. PubMed ID: 31645017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly.
    Chenlo M; Rodriguez-Gomez IA; Serramito R; Garcia-Rendueles AR; Villar-Taibo R; Fernandez-Rodriguez E; Perez-Romero S; Suarez-Fariña M; Garcia-Allut A; Cabezas-Agricola JM; Rodriguez-Garcia J; Lear PV; Alvarez-San Martin RM; Alvarez-Escola C; Bernabeu I; Alvarez CV
    EBioMedicine; 2019 May; 43():537-552. PubMed ID: 30975543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly.
    Soukup J; Hornychova H; Manethova M; Michalova K; Michnova L; Popovska L; Skarkova V; Cesak T; Netuka D; Ryska A; Cap J; Hána V; Hána V; Kršek M; Dvořáková E; Krčma M; Lazurova I; Olšovská V; Starý K; Vaňuga P; Gabalec F
    J Cell Mol Med; 2021 Mar; 25(5):2484-2492. PubMed ID: 33491286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.